Literature DB >> 19825991

PU.1 activation relieves GATA-1-mediated repression of Cebpa and Cbfb during leukemia differentiation.

Pavel Burda1, Nikola Curik, Juraj Kokavec, Petra Basova, Dana Mikulenkova, Arthur I Skoultchi, Jiri Zavadil, Tomas Stopka.   

Abstract

Hematopoietic transcription factors GATA-1 and PU.1 bind each other on DNA to block transcriptional programs of undesired lineage during hematopoietic commitment. Murine erythroleukemia (MEL) cells that coexpress GATA-1 and PU.1 are blocked at the blast stage but respond to molecular removal (downregulation) of PU.1 or addition (upregulation) of GATA-1 by inducing terminal erythroid differentiation. To test whether GATA-1 blocks PU.1 in MEL cells, we have conditionally activated a transgenic PU.1 protein fused with the estrogen receptor ligand-binding domain (PUER), resulting in activation of a myeloid transcriptional program. Gene expression arrays identified components of the PU.1-dependent transcriptome negatively regulated by GATA-1 in MEL cells, including CCAAT/enhancer binding protein alpha (Cebpa) and core-binding factor, beta subunit (Cbfb), which encode two key hematopoietic transcription factors. Inhibition of GATA-1 by small interfering RNA resulted in derepression of PU.1 target genes. Chromatin immunoprecipitation and reporter assays identified PU.1 motif sequences near Cebpa and Cbfb that are co-occupied by PU.1 and GATA-1 in the leukemic blasts. Significant derepression of Cebpa and Cbfb is achieved in MEL cells by either activation of PU.1 or knockdown of GATA-1. Furthermore, transcriptional regulation of these loci by manipulating the levels of PU.1 and GATA-1 involves quantitative increases in a transcriptionally active chromatin mark: acetylation of histone H3K9. Collectively, we show that either activation of PU.1 or inhibition of GATA-1 efficiently reverses the transcriptional block imposed by GATA-1 and leads to the activation of a myeloid transcriptional program directed by PU.1.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19825991      PMCID: PMC3193075          DOI: 10.1158/1541-7786.MCR-09-0031

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  40 in total

1.  GATA-1 interacts with the myeloid PU.1 transcription factor and represses PU.1-dependent transcription.

Authors:  C Nerlov; E Querfurth; H Kulessa; T Graf
Journal:  Blood       Date:  2000-04-15       Impact factor: 22.113

2.  Id2 intrinsically regulates lymphoid and erythroid development via interaction with different target proteins.

Authors:  Ming Ji; Huajie Li; Hyung Chan Suh; Kimberly D Klarmann; Yoshifumi Yokota; Jonathan R Keller
Journal:  Blood       Date:  2008-06-03       Impact factor: 22.113

3.  Immunology: blood lines redrawn.

Authors:  Thomas Graf
Journal:  Nature       Date:  2008-04-10       Impact factor: 49.962

4.  Reciprocal activation of GATA-1 and PU.1 marks initial specification of hematopoietic stem cells into myeloerythroid and myelolymphoid lineages.

Authors:  Yojiro Arinobu; Shin-ichi Mizuno; Yong Chong; Hirokazu Shigematsu; Tadafumi Iino; Hiromi Iwasaki; Thomas Graf; Robin Mayfield; Susan Chan; Philippe Kastner; Koichi Akashi
Journal:  Cell Stem Cell       Date:  2007-10-11       Impact factor: 24.633

5.  PU.1 and C/EBPalpha/beta convert fibroblasts into macrophage-like cells.

Authors:  Ru Feng; Sabrina C Desbordes; Huafeng Xie; Ester Sanchez Tillo; Fiona Pixley; E Richard Stanley; Thomas Graf
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-18       Impact factor: 11.205

6.  Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.

Authors:  Joshua Wechsler; Marianne Greene; Michael A McDevitt; John Anastasi; Judith E Karp; Michelle M Le Beau; John D Crispino
Journal:  Nat Genet       Date:  2002-08-12       Impact factor: 38.330

7.  HOXA9 is required for survival in human MLL-rearranged acute leukemias.

Authors:  Joerg Faber; Andrei V Krivtsov; Matthew C Stubbs; Renee Wright; Tina N Davis; Marry van den Heuvel-Eibrink; Christian M Zwaan; Andrew L Kung; Scott A Armstrong
Journal:  Blood       Date:  2008-12-03       Impact factor: 22.113

8.  Heterozygous PU.1 mutations are associated with acute myeloid leukemia.

Authors:  Beatrice U Mueller; Thomas Pabst; Motomi Osato; Norio Asou; Lisa M Johansen; Mark D Minden; Gerhard Behre; Wolfgang Hiddemann; Yoshiaki Ito; Daniel G Tenen
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

9.  Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells.

Authors:  Peggy Kirstetter; Mikkel B Schuster; Oksana Bereshchenko; Susan Moore; Heidi Dvinge; Elke Kurz; Kim Theilgaard-Mönch; Robert Månsson; Thomas A Pedersen; Thomas Pabst; Evelin Schrock; Bo T Porse; Sten Eirik W Jacobsen; Paul Bertone; Daniel G Tenen; Claus Nerlov
Journal:  Cancer Cell       Date:  2008-04       Impact factor: 31.743

10.  Aberrant DNA methylation of the transcription factor C/EBPalpha in acute myelogenous leukemia.

Authors:  Edgar Jost; Nicole do O; Stefan Wilop; James G Herman; Rainhardt Osieka; Oliver Galm
Journal:  Leuk Res       Date:  2008-08-30       Impact factor: 3.156

View more
  9 in total

Review 1.  Molecular mechanisms of ETS transcription factor-mediated tumorigenesis.

Authors:  Adwitiya Kar; Arthur Gutierrez-Hartmann
Journal:  Crit Rev Biochem Mol Biol       Date:  2013-09-25       Impact factor: 8.250

2.  C/EBPα and PU.1 exhibit different responses to RANK signaling for osteoclastogenesis.

Authors:  Joel Jules; Yi-Ping Li; Wei Chen
Journal:  Bone       Date:  2017-10-12       Impact factor: 4.398

3.  Transcriptional regulation of homeostatic and disease-associated-microglial genes by IRF1, LXRβ, and CEBPα.

Authors:  Tianwen Gao; Janna Jernigan; Syed Ali Raza; Eric B Dammer; Hailian Xiao; Nicholas T Seyfried; Allan I Levey; Srikant Rangaraju
Journal:  Glia       Date:  2019-07-13       Impact factor: 7.452

4.  A large gene network in immature erythroid cells is controlled by the myeloid and B cell transcriptional regulator PU.1.

Authors:  Sandeep N Wontakal; Xingyi Guo; Britta Will; Minyi Shi; Debasish Raha; Milind C Mahajan; Sherman Weissman; Michael Snyder; Ulrich Steidl; Deyou Zheng; Arthur I Skoultchi
Journal:  PLoS Genet       Date:  2011-06-09       Impact factor: 5.917

5.  PU.1 and Haematopoietic Cell Fate: Dosage Matters.

Authors:  Ka Sin Mak; Alister P W Funnell; Richard C M Pearson; Merlin Crossley
Journal:  Int J Cell Biol       Date:  2011-08-10

6.  GATA-1 Inhibits PU.1 Gene via DNA and Histone H3K9 Methylation of Its Distal Enhancer in Erythroleukemia.

Authors:  Pavel Burda; Jarmila Vargova; Nikola Curik; Cyril Salek; Giorgio Lucio Papadopoulos; John Strouboulis; Tomas Stopka
Journal:  PLoS One       Date:  2016-03-24       Impact factor: 3.240

7.  PU.1-c-Jun interaction is crucial for PU.1 function in myeloid development.

Authors:  Xinhui Zhao; Boris Bartholdy; Yukiya Yamamoto; Erica K Evans; Meritxell Alberich-Jordà; Philipp B Staber; Touati Benoukraf; Pu Zhang; Junyan Zhang; Bon Q Trinh; John D Crispino; Trang Hoang; Mahmoud A Bassal; Daniel G Tenen
Journal:  Commun Biol       Date:  2022-09-14

8.  Epigenetic control of SPI1 gene by CTCF and ISWI ATPase SMARCA5.

Authors:  Martina Dluhosova; Nikola Curik; Jarmila Vargova; Anna Jonasova; Tomas Zikmund; Tomas Stopka
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240

9.  Synergistic anti-AML effects of the LSD1 inhibitor T-3775440 and the NEDD8-activating enzyme inhibitor pevonedistat via transdifferentiation and DNA rereplication.

Authors:  Y Ishikawa; K Nakayama; M Morimoto; A Mizutani; A Nakayama; K Toyoshima; A Hayashi; S Takagi; R Dairiki; H Miyashita; S Matsumoto; K Gamo; T Nomura; K Nakamura
Journal:  Oncogenesis       Date:  2017-09-11       Impact factor: 7.485

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.